ArticleJournal of the International Neuropsychological Society : JINS2025
Assessing Stages of Objective Memory Impairment and neuroimaging as risk factors of incident cognitive impairment.
Kellen K Petersen, Ali Ezzati, Bhargav T Nallapu, Richard B Lipton, Reisa A Sperling, Kathryn V Papp, Dorene M Rentz, Keith A Johnson, Ellen Grober
Abstract read
In one paragraphArticle in Journal of the International Neuropsychological Society : JINS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
9 authors.
Kellen K PetersenDepartment of Neurology, Albert Einstein College of Medicine, New York City, NY, USA.
Ali EzzatiDepartment of Neurology, Albert Einstein College of Medicine, New York City, NY, USA.
Bhargav T NallapuDepartment of Neurology, Albert Einstein College of Medicine, New York City, NY, USA.
Richard B LiptonDepartment of Neurology, Albert Einstein College of Medicine, New York City, NY, USA.
Reisa A SperlingBrigham and Women's Hospital, Boston, MA, USA.
Kathryn V PappBrigham and Women's Hospital, Boston, MA, USA.
Dorene M RentzBrigham and Women's Hospital, Boston, MA, USA.
Keith A JohnsonMassachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Funding
Vascular Structure and Function in Cognitive AgingP01AG003949 · NIA · YESHIVA UNIVERSITY · PI Richard B. LIPTON · 1985 to 2026
$73.9MVascular factors, physical activity, and inflammation as modulators of neurodegenerative and cognitive trajectories (Project 2)P01AG036694 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI Rachel Frances Buckley, Keith A. Johnson · 2010 to 2026
$50.2MMRI Measures of Cerebrovascular Injury and AD Atrophy in a Study of LatinosRF1AG054548 · NIA · UNIVERSITY OF CALIFORNIA AT DAVIS · PI DECARLI, CHARLES, GONZALEZ, HECTOR M · 2017 to 2017
$14.7MValidation of the Remote Cognitive Aging and Alzheimer’s Disease REsearch (R-CARE) Toolbox for Diverse PopulationsR01AG080635 · NIA · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI Ali Ezzati, Richard B. LIPTON · 2023 to 2026
$8.6MStudy of Latinos-Investigation of Neurocognitive Aging (SOL-INCA)R01AG048642 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GONZALEZ, HECTOR M · 2015 to 2019
$5.7MApplication of ambulatory methods for assessing short- and long-term associations of sleep health with cognitive decline in older adultsR01AG062622 · NIA · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI BUXTON, ORFEU M, DERBY, CAROL A. · 2019 to 2022
$3.1MCOSMIC: An international consortium to identify risk and protective factors and biomarkers of cognitive ageing and dementia in diverse ethno-racial groups and geographical settingsRF1AG057531 · NIA · UNIVERSITY OF NEW SOUTH WALES · PI SACHDEV, PERMINDER S · 2017 to 2020
$2.9MThe role of personality in cognitive aging and dementiaR01AG060933 · NIA · STATE UNIVERSITY NEW YORK STONY BROOK · PI SCOTT, STACEY BETH · 2019 to 2023
$2.4MEinstein Center for Excellence for Clinical Trials in NeuroscienceU10NS077308 · NINDS · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI LIPTON, RICHARD B., SHINNAR, SHLOMO · 2011 to 2017
$2.2MThe biological underpinnings of Motoric Cognitive Risk syndrome: a multi-center studyR56AG057548 · NIA · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI VERGHESE, JOE · 2017 to 2017
$1.2MPredictive analytics for cognitive decline and Alzheimer’s diseaseK23AG063993 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI EZZATI, ALI · 2020 to 2024
$984kEarly Phase Pain Investigation Clinical Network: Greater New York Clinical CenterU24NS113847 · NINDS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI DOAN, LISA, LIPTON, RICHARD B. · 2019 to 2019
$966kFDA HHS UG3 FD006795NIA NIH HHS K23 AG063993NIA NIH HHS P01 AG003949NIA NIH HHS P01 AG036694NIA NIH HHS R01 AG048642NIA NIH HHS R01 AG060933NIA NIH HHS R01 AG062622NIA NIH HHS R01 AG080635NIA NIH HHS R21 AG056920NIA NIH HHS R56 AG057548NIA NIH HHS RF1 AG054548NIA NIH HHS RF1 AG057531NINDS NIH HHS U10 NS077308NINDS NIH HHS U24 NS113847
6 · The paper itselfAbstract
objectiveThe Stages of Objective Memory Impairment (SOMI) system, based on the Free and Cued Selective Reminding Test (FCSRT), is a potential marker of subtle cognitive impairment in cognitively normal persons defined by a Clinical Dementia Rating (CDR) = 0. We investigated SOMI's ability to predict incident cognitive impairment (CDR >0) in combination with demographic features and neuroimaging biomarkers.
methodsCognitively unimpaired participants (CDR = 0) from the Harvard Aging Brain Study had baseline FCSRT scores, MRI, FDG-PET, and PiB-PET as well as follow-up CDRs for 5 years. Cox proportional hazards models with correction for multiple testing assessed the predictive validity of SOMI and neuroimaging biomarkers for progression (CDR >0). Comprehensive sensitivity analyses examined alternative outcomes and stricter screening criteria.
resultsParticipants (
conclusionsSOMI stages predict progression to incident cognitive impairment with SOMI-3/4 maintaining significance after rigorous multiple testing correction. Entorhinal thickness provides the strongest biomarker enhancement to prediction models. SOMI demonstrates substantial incremental predictive value beyond standard demographic and biomarker predictors.
Indexed as
Cognitive DysfunctionMemory DisordersNeuroimagingAgedAged, 80 and overDisease ProgressionFemaleFollow-Up StudiesHumansIncidenceMagnetic Resonance ImagingMaleNeuropsychological TestsPositron-Emission TomographyRisk Factorsbiomarkersentorhinal corexFree and Cued Selective Reminding Testincident cognitive impairmentmemoryStages of Objective Memory Impairment
Identifiers
PMID40842062
PMCPMC12418808
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390